Innovative Medical Management (002173.SZ) affiliated company Quan Zhen Medical plans to advance Series B financing.

Innovative Medical Management (002173.SZ) announcement, the company's affiliated company Quan Jian Medical needs to carry out B+ round financing for business development, and has decided to accept investment from PwC Small and Medium Term Venture Capital Enterprise (Hangzhou) (referred to as "PwC Small and Medium"), Changzhou Hengnuo Intelligent Entrepreneurship & Innovation Fund Partnership Enterprise (referred to as "Changzhou Hengnuo"), and Hangzhou High-level Talent Innovation Entrepreneurship & Innovation Fund Partnership Enterprise (referred to as "Talent Fund"). Recently, the company's board of directors approved the resolution on "Approval of the Signing of Quan Jian Medical's B+ Round Capital Increase Agreement, B+ Round Shareholder Agreement, and Related Documents". According to the Quan Jian Medical's "B+ Round Capital Increase Agreement", the capital increase plan for this round is as follows: PwC Small and Medium will contribute 20 million RMB in cash, subscribing to Quan Jian Medical's newly registered capital of 1.180579 million RMB for this B+ round; Changzhou Hengnuo will contribute 5 million RMB in cash, subscribing to Quan Jian Medical's newly registered capital of 0.295145 million RMB for this B+ round; Talent Fund will contribute 5 million RMB in cash, subscribing to Quan Jian Medical's newly registered capital of 0.295145 million RMB for this B+ round. Quan Jian Medical's registered capital will increase to 16.528106 million RMB, with PwC Small and Medium, Changzhou Hengnuo, and Talent Fund respectively obtaining 7.1429%, 1.7857%, and 1.7857% of Quan Jian Medical's equity after this capital increase. After the implementation of this capital increase and conversion plan, the company's proportion of investment will be 16.5160%.